Supplemental Material: Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa

Supplemental Material for the manuscript titled "Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension", published in the Journal of the American Academy of Dermatology.

Contents:
Supplementary Methods 1. Prespecified safety topics of interest
Supplementary Figure 1: BE HEARD I and II and BE HEARD Extension study design
Supplementary Figure 2: Safety pooled data
Supplementary Figure 3: Missing data handling
Supplementary Figure 4: HiSCR50/75/90/100 over time in BKZ Total patients (mNRI [AE-LoE])
Supplementary Figure 5: Efficacy- and lesion-based outcomes over time in BKZ Total patients (MI [AE-LoE] and mNRI [AE-LoE])
Supplementary Table 1. HiSCR50/75/90/100 to Week 96 in patients receiving BKZ Q2W/Q4W/Q4W (OC)